Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections-Reference-Cited by-同舟云学术

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

Published:2017-03 Issue:3 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Castón Juan José¹²,De la Torre Álvaro³,Ruiz-Camps Isabel⁴,Sorlí María Luisa⁵,Torres Vicente⁶,Torre-Cisneros Julián¹²⁷

Affiliation:

1. Clinical Unit of Infectious Diseases, Hospital Universitario Reina Sofía-Instituto Maimónides de Investigación Biomédica (IMIBIC), Córdoba, Spain

2. Spanish Network for the Research in Infectious Diseases (REIPI RD12/2015), Instituto de Salud Carlos III, Madrid, Spain

3. Service of Anesthesiology and Reanimation, Hospital de Jaen, Jaen, Spain

4. Department of Infectious Diseases, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

5. Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain

6. Service of Anesthesia and Reanimation, Hospital Universitario Son Espases, Palma de Mallorca, Spain

7. Universidad de Córdoba, Córdoba, Spain

Abstract

ABSTRACT Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02136-16

Reference15 articles.

1. Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study

2. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001)

3. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections

4. New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa

5. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of inadequate empiric therapy and timing of newer antibacterial therapy in hospitalized adults with culture-positive Enterobacterales and Pseudomonas aeruginosa: a multicenter analysis;BMC Infectious Diseases;2024-08-09

2. Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings—A French Real-world Study;Open Forum Infectious Diseases;2024-02-01

3. Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments;Antibiotics;2023-11-12

4. Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis;Enfermedades infecciosas y microbiologia clinica (English ed.);2023-10

5. Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates;Medicina;2023-03-07